Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
Kashif M Munir,1 Stephen N Davis2 1Division of Endocrinology, Diabetes, and Nutrition, Center for Diabetes and Endocrinology, 2Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA Abstract: With rates of obesity and diabetes rising across the world, effective therap...
Guardado en:
Autores principales: | Munir KM, Davis SN |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/de0b37de21c147caa6d1c75c365dd912 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu S, et al.
Publicado: (2019) -
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou I, et al.
Publicado: (2019) -
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
por: Liu Y, et al.
Publicado: (2021) -
Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019) -
Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus
por: Ojha A, et al.
Publicado: (2019)